SCHEMBL5328124

SCHEMBL5328124

CCOCCn1c(=O)cc(-c2ccc(C)cc2)n(-c2ccc(SC)cc2)c1=O

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.37
PGR P06401 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CHRM1 P11229 1/20 0.35
TBXA2R P21731 1/20 0.35
PTGS1 P23219 1/20 0.35
SLC6A2 P23975 1/20 0.35
PDE4A P27815 1/20 0.35
ADRA1A P35348 1/20 0.35
DRD3 P35462 1/20 0.35
HSD17B10 Q99714 2/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
THRB P10828 1/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP2C9 P11712 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5325697 0.85 RAD51 (0.40) PTGS2PTGS1TSHRSMN1; SMN2THRB
SCHEMBL5320985 0.83 PTGS2 (0.43) PTGS2PTGS1SMN1; SMN2THRBTDP1
SCHEMBL5331474 0.82 PTGS2 (0.38) PTGS2PTGS1SMN1; SMN2THRBCYP2C9
SCHEMBL5330480 0.82 THRB (0.36) PTGS2PTGS1SMN1; SMN2THRBCYP2C9
SCHEMBL5324453 0.81 CSF1R (0.40) PTGS2PTGS1THRBCYP2C9HTT
SCHEMBL5320843 0.80 DRD2 (0.44) PTGS2PTGS1DRD3SMN1; SMN2THRB
SCHEMBL5296183 0.79 POLB (0.34) PTGS2PTGS1SMN1; SMN2THRBPOLB
SCHEMBL5325596 0.79 MEN1 (0.41) HSD17B10POLBTDP1HTT
SCHEMBL14624160 0.79 HTT (0.35) PTGS2PTGS1TSHRSMN1; SMN2THRB
SCHEMBL5297375 0.79 MEN1 (0.42) PTGS2HSD17B10SMN1; SMN2POLBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007007161-A2 NOVEL BIO-ACTIVE DERIVATIVES ORCHID RESEARCH LABORATORIES LIMITED (IN) 2007-01-18 WO claimed
US-20070299113-A1 Metabotropic glutamate receptor modulators MERZ PHARMA GMBH & CO. KGAA (DE) 2007-12-27 US disclosed
WO-2007148113-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2007-12-27 WO disclosed
WO-2007007161-A2 NOVEL BIO-ACTIVE DERIVATIVES ORCHID RESEARCH LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed
WO-2007007161-A2 NOVEL BIO-ACTIVE DERIVATIVES ORCHID RESEARCH LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299113-A1 Metabotropic glutamate receptor modulators GRM1, GRM2, GRM3 PTGS2 753/4885PGR 1330/4885ADORA3 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.